Trevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022
Trevi Therapeutics (Nasdaq: TRVI) will host a conference call and live audio webcast on August 11, 2022, at 4:30 p.m. ET, to discuss its Q2 2022 financial results and provide a corporate update. The company is developing Haduvio (oral nalbuphine ER) as a treatment for prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis. Haduvio has received FDA Fast Track designation for the treatment of itch. More information can be accessed on the company’s website.
- Haduvio received FDA Fast Track designation for treating itch in prurigo nodularis.
- Conference call scheduled to provide updates and financial results indicating transparency.
- None.
Conference call and webcast to be held at 4:30 p.m. EDT
NEW HAVEN, Conn., Aug. 4, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis (IPF), today announced that management will host a conference call and live audio webcast on Thursday, August 11, 2022, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the second quarter ended June 30, 2022.
To participate in the live conference call by phone, please dial (888) 317 6003 (domestic) or (412) 317 6061 (international) and provide access code 9437525. A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio for the treatment of prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.
Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.
Haduvio, an investigational therapy, is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. The ĸ- and µ-opioid receptors are known to be critical mediators of itch, cough and certain movement disorders. Nalbuphine's mechanism of action may also mitigate the risk of abuse associated with µ-opioid agonists because it antagonizes, or blocks, µ-opioid receptors. Parenteral nalbuphine is not currently scheduled as a controlled substance by the DEA in the United States or by regulatory authorities in most of Europe. Trevi intends to propose Haduvio as the trade name for nalbuphine ER. Nalbuphine ER has been granted Fast Track designation by the FDA for the treatment of itch in patients with prurigo nodularis. Its safety and efficacy have not been evaluated by any regulatory authority.
Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-report-q2-2022-financial-results-and-provide-a-corporate-update-on-august-11-2022-301600493.html
SOURCE Trevi Therapeutics, Inc.
FAQ
When will Trevi Therapeutics report its Q2 2022 financial results?
What is Haduvio and how is it being developed?
What time is the Trevi Therapeutics conference call?
